Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease
- 25 August 2020
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 102 (4), 654-662
- https://doi.org/10.1159/000509852
Abstract
Background/Aims: Lusutrombopag, a small-molecule thrombopoietin receptor agonist, is used to treat thrombocytopenia based on the results of a phase 3 trial, including data for single-use administration in patients with chronic liver disease (CLD) undergoing invasive procedures. We aimed to evaluate the efficacy and safety of repeated lusutrombopag use. Methods: Lusutrombopag was administered repeatedly in patients undergoing multi-cycle invasive procedures at intervals >1 month. Results: Data from 8 patients (median platelet count at baseline, 44.0 [range, 35–49] × 109/L) and 25 cycles of invasive procedures, including 2 cycles in 3 patients, 3 cycles in 4 patients, and 7 cycles in 1 patient, were retrospectively evaluated. The procedures included 18 transarterial chemoembolizations, 5 radiofrequency ablations, and 2 liver needle biopsies. Platelet counts increased significantly compared with baseline, and median changes in platelet counts were 46.0 × 109/L (p = 0.012) in cycle 1, 44.0 × 109/L (p = 0.012) in cycle 2, and 42.0 × 109/L (p = 0.008) in cycles 3–7. No severe adverse events, including portal vein thrombus or bleeding, were observed. Conclusions: Repeated use of lusutrombopag might be safe and effective against thrombocytopenia in patients with CLD undergoing multi-cycle invasive procedures, although long-term data from more patients are required.Keywords
This publication has 23 references indexed in Scilit:
- Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)British Journal of Haematology, 2012
- Incidence of Bleeding Following Invasive Procedures in Patients With Thrombocytopenia and Advanced Liver DiseaseClinical Gastroenterology and Hepatology, 2010
- Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostimBlood, 2009
- Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated CirrhosisClinical Gastroenterology and Hepatology, 2009
- Thrombocytopenia associated with chronic liver diseaseJournal of Hepatology, 2008
- Review article: thrombocytopenia in chronic liver diseaseAlimentary Pharmacology & Therapeutics, 2007
- Evidence-Based Platelet Transfusion GuidelinesHematology, 2007
- Coagulation Abnormalities in Patients Who Have Liver DiseaseClinics in Liver Disease, 2006
- Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment optionsAlimentary Pharmacology & Therapeutics, 2006
- Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in miceBone Marrow Transplantation, 2001